Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
ExchangeRight Income Fund
Dilutive issuance
confidence 95%
filed 2026-05-20
Item 3.02
The Company disclosed the sale of 30,481 Class D Common Shares for $840,000 under a continuous private placement offering of up to $2.165 billion in unregistered equity securities pursuant to Section 4(a)(2) and Regulation D Rule 506(c). This is a classic dilutive issuance of unregistered equity securities, and the forward-looking statements explicitly warn that "future sales or issuances of our Common Shares or other securities convertible into our Common Shares, or the perception thereof, could cause the value of our Common Shares to decline and could result in dilution."
View raw filing on EDGAR →
Grayscale Bittensor Trust (TAO)
Dilutive issuance
confidence 95%
filed 2026-05-20
Item 3.02
The filing discloses an unregistered sale of 211,900 Shares in a private placement to accredited investors under Rule 506(c) of Regulation D, representing an aggregate of 4,038.87 TAO worth $1,149,569. This is a classic dilutive issuance exempt from registration requirements, with Grayscale Securities acting as Authorized Participant and potential underwriter. The disclosure explicitly references Item 3.02 (Unregistered Sales of Equity Securities) and notes that periodic share creation may constitute ongoing distributions.
View raw filing on EDGAR →
AB Private Lending Fund
Dilutive issuance
confidence 92%
filed 2026-05-20
Item 3.02
The filing discloses an unregistered sale of 4,045 Class I common shares of beneficial interest to feeder vehicles, exempt under Section 4(a)(2) and Regulation S. This is a classic private placement of equity securities that dilutes existing shareholders and raises capital for the Fund. The transaction is material to investors assessing the Fund's capitalization and ownership structure.
View raw filing on EDGAR →
AKAMAI TECHNOLOGIES INC
Dilutive issuance
confidence 92%
filed 2026-05-20
Item 8.01
Akamai announced the pricing of $3 billion in aggregate principal amount of convertible senior notes ($1.5 billion due 2030 and $1.5 billion due 2032) in a private offering to qualified institutional buyers. This is a material dilutive issuance of convertible debt securities that will likely result in equity dilution upon conversion, consistent with Item 3.02 disclosure requirements and the dilutive_issuance event type.
View raw filing on EDGAR →
Cenntro Inc.
Dilutive issuance
confidence 92%
filed 2026-05-20
Item 1.01
The filing discloses entry into securities purchase agreements for a private placement of 1,000,000 shares of common stock at $3.93 per share for approximately $3.93 million in gross proceeds. The disclosure explicitly notes compliance with Nasdaq Listing Rule 5635(d) permitting issuance of 20% or more of outstanding common stock without shareholder approval, indicating material dilution. This is a classic dilutive equity issuance requiring Item 1.01 disclosure under Rule 8-K.
View raw filing on EDGAR →
Cenntro Inc.
Dilutive issuance
confidence 92%
filed 2026-05-20
Item 3.02
Item 3.02 discloses an unregistered private placement of common stock exempt under Section 4(a)(2) and Regulation S, with shares subject to transfer restrictions and legend requirements. This is a classic dilutive issuance of equity securities outside registered offerings, material to investors assessing ownership dilution and capital structure.
View raw filing on EDGAR →
CareTrust REIT, Inc.
Dilutive issuance
confidence 95%
filed 2026-05-20
Item 8.01
CareTrust REIT completed a registered public offering of 12.5 million shares of common stock at $40.225 per share on May 20, 2026, with an additional 1.875 million shares available under an underwriter option. The offering was conducted through a forward sale structure with Wells Fargo and JPMorgan Chase as forward purchasers. This is a material dilutive equity issuance that increases the company's share count and raises capital, disclosed pursuant to an effective S-3 shelf registration statement.
View raw filing on EDGAR →
NANOVIRICIDES, INC.
Dilutive issuance
confidence 95%
filed 2026-05-20
Item 1.01
NanoViricides entered into a Securities Purchase Agreement on May 15, 2026, for a registered direct offering of 1,133,334 shares of common stock at $1.50 per share, pre-funded warrants, and common warrants, generating approximately $2.0 million in gross proceeds. This is a material equity issuance that dilutes existing shareholders and raises capital through the sale of registered securities, fitting the dilutive_issuance classification.
View raw filing on EDGAR →
NANOVIRICIDES, INC.
Dilutive issuance
confidence 85%
filed 2026-05-20
Item 8.01
The filing discloses an "Offering" announced on May 15, 2026 and closed on May 18, 2026, with press releases attached as exhibits. While the specific terms are not detailed in this Item 8.01 excerpt, the structure and timing of dual announcements (announcement and closing) is consistent with a securities offering. For a small-cap company like Nanoviricides, an offering disclosed via 8-K Item 8.01 typically represents a dilutive equity issuance or capital raise that would be material to investors.
View raw filing on EDGAR →
Annovis Bio, Inc.
Dilutive issuance
confidence 95%
filed 2026-05-20
Item 1.01
Annovis Bio entered into an Underwriting Agreement on May 20, 2026 to issue 7,895,000 shares of common stock and 7,105,500 warrants in a public offering expected to raise approximately $15 million in gross proceeds. This is a material dilutive equity issuance disclosed under Item 1.01, with the company planning to use net proceeds for clinical development and working capital—a typical capital raise by a biotech company.
View raw filing on EDGAR →
Annovis Bio, Inc.
Dilutive issuance
confidence 85%
filed 2026-05-20
Item 7.01
The disclosure announces the launch and pricing of an "Offering" via press releases on May 19-20, 2026. While the Item 7.01 filing itself does not specify the offering type, the context of a public company announcing an offering launch and pricing strongly suggests a capital raise (likely equity or convertible securities). Such offerings are material to investors as they affect ownership dilution and the company's capital structure. The high confidence reflects the clear language around "launch" and "pricing" of an offering, though the specific instrument type is not explicitly stated in this excerpt.
View raw filing on EDGAR →
Golden Minerals Co
Dilutive issuance
confidence 95%
filed 2026-05-20
Item 1.01
Golden Minerals entered into a Subscription Agreement for a private placement of 3,740,000 common shares at $0.2290 per share, raising approximately $856,463 in gross proceeds. The shares are being issued under Section 4(a)(2) and Regulation D/S without registration, which is the hallmark of a dilutive private equity issuance. This materially dilutes existing shareholders and is a significant capital-raising event for the company.
View raw filing on EDGAR →
Golden Minerals Co
Dilutive issuance
confidence 85%
filed 2026-05-20
Item 3.02
Item 3.02 explicitly addresses unregistered sales of equity securities. Golden Minerals Co's disclosure under this Item indicates a dilutive issuance event. While the section text provided is incomplete, the Item heading and filing structure confirm this is a material equity offering that would affect shareholder dilution and the registrant's capital structure.
View raw filing on EDGAR →
Stone Point Credit Income Fund
Dilutive issuance
confidence 95%
filed 2026-05-20
Item 3.02
Stone Point Credit Income Fund disclosed an unregistered sale of 110,889.543 common shares at net asset value of $24.7599 for aggregate proceeds of $2,745,614, conducted pursuant to Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive private placement by a fund raising capital from accredited investors without public registration, directly matching the dilutive_issuance taxonomy.
View raw filing on EDGAR →
Red Cat Holdings, Inc.
Dilutive issuance
confidence 92%
filed 2026-05-20
Item 3.02
Red Cat Holdings issued unregistered "Closing Shares" as consideration in an acquisition, with potential for additional contingent share issuances tied to integration, revenue, and gross margin milestones. The disclosure explicitly references Item 3.02 (Unregistered Sales of Securities) and describes reliance on Section 4(a)(2) and Regulation D exemptions, which are hallmarks of private equity issuances. The contingent nature and acquisition context make this a material dilutive event for existing shareholders.
View raw filing on EDGAR →
Blue Owl Digital Infrastructure Trust
Dilutive issuance
confidence 95%
filed 2026-05-19
Item 3.02
Blue Owl Digital Infrastructure Trust sold 2,090,696 common shares across multiple classes (S, D, and I) for approximately $21.7 million in gross proceeds on May 1, 2026, pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions. This is a classic unregistered private placement of equity securities that dilutes existing shareholders and raises capital, fitting squarely within the dilutive_issuance category. The materiality is clear given the substantial proceeds and share count involved.
View raw filing on EDGAR →
Ares Core Infrastructure Fund
Dilutive issuance
confidence 95%
filed 2026-05-19
Item 3.02
The Fund sold 28.76 million Common Shares across four classes for an aggregate purchase price of $715.5 million in an unregistered offering exempt under Section 4(a)(2) and Regulation D (Rule 506(b)). This is a material dilutive issuance of equity securities disclosed under Item 3.02, representing a substantial capital raise that would affect investor assessment of share dilution and fund capitalization.
View raw filing on EDGAR →
Blue Owl Real Estate Net Lease Trust
Dilutive issuance
confidence 92%
filed 2026-05-19
Item 3.02
Blue Owl Real Estate Net Lease Trust sold 3,452,243 shares of Class I common shares for approximately $36.8 million in an unregistered offering exempt under Section 4(a)(2), Regulation D, and/or Regulation S. This is a classic dilutive issuance of equity securities to feeder vehicles, disclosed under Item 3.02, representing a material capital raise that would affect investor assessment of share dilution and the company's financing activities.
View raw filing on EDGAR →
Sunshine Biopharma Inc.
Dilutive issuance
confidence 95%
filed 2026-05-19
Item 1.01
Sunshine Biopharma entered into a placement agent agreement for a public offering of 11.16 million Common Units and 840,000 Pre-Funded Units, generating approximately $6 million in gross proceeds. The offering includes pre-funded warrants exercisable at $0.00001 and Series C warrants exercisable at $0.50, both of which are highly dilutive instruments. This is a classic dilutive equity issuance disclosed under Item 1.01, material to investors assessing ownership dilution and capital structure.
View raw filing on EDGAR →
Sunshine Biopharma Inc.
Dilutive issuance
confidence 92%
filed 2026-05-19
Item 8.01
The filing discloses the pricing and closing of an offering involving pre-funded warrants and Series C warrants, as evidenced by the Placement Agent Agreement and warrant forms filed as exhibits. This represents a dilutive equity issuance that would materially affect existing shareholders' ownership percentages and is a significant capital-raising event for a small-cap biopharmaceutical company.
View raw filing on EDGAR →
iPower Inc.
Dilutive issuance
confidence 92%
filed 2026-05-19
Item 1.01
iPower Inc. completed an Additional Optional Closing on May 19, 2026, issuing $3,000,000 principal amount of Series A senior secured convertible notes to an institutional investor in reliance on Regulation D exemption from registration. The convertible notes are dilutive equity instruments with a fixed conversion price of $1.03, and the company received approximately $2,820,000 in gross proceeds. This is a material private placement of convertible securities that would affect a reasonable investor's assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
DATA I/O CORP
Dilutive issuance
confidence 95%
filed 2026-05-19
Item 3.02
Item 3.02 is the dedicated 8-K Item for unregistered sales of equity securities, including private placements and convertible offerings. This disclosure is material as it represents potential dilution to existing shareholders and is a common signal of capital-raising activity, particularly at smaller-cap issuers like DATA I/O CORP.
View raw filing on EDGAR →
ARES STRATEGIC INCOME FUND
Dilutive issuance
confidence 92%
filed 2026-05-19
Item 3.02
The Fund sold 1,934,637 Class I common shares for $52.1 million during May 2026 in an unregistered offering exempt under Section 4(a)(2) and Regulation S. This is a classic dilutive equity issuance disclosed under Item 3.02, representing a material capital raise that increases share count and dilutes existing shareholders.
View raw filing on EDGAR →
MOBIX LABS, INC
Dilutive issuance
confidence 85%
filed 2026-05-19
Item 2.03
Leviston converted $4 million of principal under a convertible note into 2,500,000 shares of Common Stock between May 12-18, 2026. This is a dilutive equity issuance resulting from debt conversion, which materially increases share count and dilutes existing shareholders. The conversion of a substantial debt obligation into equity is a material capital structure event.
View raw filing on EDGAR →
GeoVax Labs, Inc.
Dilutive issuance
confidence 95%
filed 2026-05-19
Item 1.01
GeoVax Labs entered into a securities purchase agreement on May 18, 2026 for an unregistered private placement of pre-funded warrants and common warrants to purchase up to 6,081,081 shares of common stock, raising approximately $2.7 million in net proceeds. The securities were issued under Section 4(a)(2) and Regulation D exemptions, and the filing explicitly notes the securities "have not been registered under the Securities Act." This is a classic dilutive issuance—an unregistered equity offering that will substantially increase share count upon warrant exercise, materially affecting existing shareholders.
View raw filing on EDGAR →
GeoVax Labs, Inc.
Dilutive issuance
confidence 92%
filed 2026-05-19
Item 3.02
Item 3.02 discloses unregistered sales of equity securities—specifically Pre-Funded Warrants and Common Warrants issued under Section 4(a)(2) and Rule 506(b) of Regulation D. This is a classic private placement of warrant instruments that will dilute existing shareholders upon exercise. The filing explicitly references warrant forms and future issuance of Common Warrant Shares, indicating a capital raise through dilutive equity instruments.
View raw filing on EDGAR →
GeoVax Labs, Inc.
Dilutive issuance
confidence 72%
filed 2026-05-19
Item 7.01
The filing discloses pricing of an "Offering" via press release on May 18, 2026, filed under Item 7.01 (Regulation FD Disclosure). While the specific terms are not detailed in the excerpt, the reference to "pricing of the Offering" strongly suggests an equity or convertible securities issuance. The use of Item 7.01 rather than Item 3.02 (Unregistered Sales) is consistent with a registered offering, but the disclosure of pricing is material to investors assessing potential dilution and capital structure changes.
View raw filing on EDGAR →
Zoomcar Holdings, Inc.
Dilutive issuance
confidence 92%
filed 2026-05-19
Item 3.02
The filing discloses unregistered sales of equity securities under Item 3.02, specifically: (1) issuance to ACM in satisfaction of a judgment obligation under Section 4(a)(2) and Rule 506 of Regulation D, and (2) issuance of Reimer Settlement Shares under Section 3(a)(10). These are classic dilutive equity issuances used to settle obligations, which materially affect shareholder equity and voting power.
View raw filing on EDGAR →
EagleRock Land, LLC
Dilutive issuance
confidence 75%
filed 2026-05-19
Item 1.01
EagleRock Land, LLC entered into an underwriting agreement on May 13, 2026, for the offer and sale of 17.3 million Class A shares at $18.50 per share, with an additional 2.595 million shares issued via an exercised option, generating approximately $333.1 million in net proceeds. While this is a registered public offering (not an unregistered private placement), the substantial equity issuance and capital raise are material events that would affect investor assessment. The taxonomy's "dilutive_issuance" category emphasizes unregistered sales and PIPEs, but this registered IPO-like offering is the most salient material event disclosed and fits the spirit of equity dilution disclosure, though a registered offering is less typical for this category.
View raw filing on EDGAR →
EagleRock Land, LLC
Dilutive issuance
confidence 85%
filed 2026-05-19
Item 3.02
Item 3.02 discloses unregistered sales of equity securities relying on Section 4(a)(2) exemption. The Warrant Exercise Agreement dated May 4, 2026, involved warrant holders exercising L&E Warrants to purchase units and receiving OpCo Units and Class B shares in redemption, followed by merger transactions resulting in issuance of Class A shares. This constitutes a dilutive equity issuance undertaken outside registered offerings, typical of private placements or restructuring transactions involving equity conversion.
View raw filing on EDGAR →
EagleRock Land, LLC
Dilutive issuance
confidence 75%
filed 2026-05-19
Item 7.01
The filing discloses a press release announcing "the pricing of the Offering" on May 13, 2026. While the specific terms are not detailed in the Item 7.01 text itself, the announcement of an offering pricing is a classic signal of a dilutive equity issuance. The furnishing under Regulation FD and the reference to an offering pricing strongly suggest a capital raise that would dilute existing shareholders, consistent with dilutive_issuance classification.
View raw filing on EDGAR →
Jaguar Health, Inc.
Dilutive issuance
confidence 92%
filed 2026-05-19
Item 3.02
Item 3.02 explicitly discloses unregistered sales of equity securities—Common Exchange Shares and Series Q Preferred Stock—issued under Section 3(a)(9) of the Securities Act. This is a classic dilutive issuance event. The incorporation by reference to Item 1.01 suggests a material transaction (likely a debt conversion or exchange), and the use of the Section 3(a)(9) exemption is typical for private equity issuances that signal cash-raising or restructuring activity.
View raw filing on EDGAR →
Sabre Corp
Dilutive issuance
confidence 75%
filed 2026-05-19
Item 1.01
Sabre issued $150 million of exchangeable senior notes convertible into common stock at an initial exchange price of approximately $2.24 per share. While technically a debt issuance, the exchangeable feature creates significant dilution potential to existing shareholders, particularly given the conversion mechanics and the ability of holders to exchange into common stock. This is a material capital-raising event with equity dilution consequences.
View raw filing on EDGAR →
Sabre Corp
Dilutive issuance
confidence 95%
filed 2026-05-19
Item 3.02
Sabre issued exchangeable notes in a private placement relying on Section 4(a)(2) exemption from registration, with potential dilution of 67–87 million shares of common stock upon exchange. This is a classic unregistered equity issuance (Item 3.02) that materially dilutes existing shareholders and signals capital-raising activity typical of small- to mid-cap issuers under financial pressure.
View raw filing on EDGAR →
Sabre Corp
Dilutive issuance
confidence 85%
filed 2026-05-19
Item 8.01
Sabre entered into privately-negotiated purchase agreements with accredited investors and qualified institutional buyers to issue "New Exchangeable Notes," which are exchangeable into equity and thus dilutive to existing shareholders. The filing discloses that net proceeds were used to repurchase $100 million of existing exchangeable notes, with intent to retire the remaining $50 million, indicating a material capital structure transaction. This is a classic dilutive issuance under Item 3.02 taxonomy, disclosed here under Item 8.01.
View raw filing on EDGAR →
Blackstone Digital Infrastructure Trust Inc.
Dilutive issuance
confidence 85%
filed 2026-05-19
Item 8.01
The filing discloses completion of an initial public offering of 87.5 million shares at $20.00 per share, with underwriters exercising a full 30-day option for additional shares, resulting in gross proceeds of $2.0 billion. While this is technically a registered offering (not an unregistered private placement), the massive capital raise and resulting dilution to investors is material and represents the company's entry into public markets. The dilutive_issuance category best captures the equity issuance event, though this is a registered IPO rather than a typical PIPE or private placement.
View raw filing on EDGAR →
Apollo Debt Solutions BDC
Dilutive issuance
confidence 95%
filed 2026-05-19
Item 3.02
Apollo Debt Solutions BDC sold 384,867 unregistered Class I Common Shares for $9.2 million to feeder vehicles, relying on Section 4(a)(2) and Regulation S exemptions. This is a classic dilutive private placement of equity securities that would materially affect shareholder ownership and the total mix of information available to investors regarding capitalization and dilution.
View raw filing on EDGAR →
Galera Therapeutics, Inc.
Dilutive issuance
confidence 75%
filed 2026-05-19
Item 8.01
The Company converted 42,839.11 shares of Series B Non-Voting Convertible Preferred Stock into 42,839,103 shares of common stock on May 15, 2026, resulting in a substantial increase in common share count (approximately 1,000x conversion ratio). This mandatory conversion of preferred stock into common stock is a dilutive issuance that materially increases the equity base and would affect a reasonable investor's assessment of ownership dilution and voting power, even though the conversion was contractually mandated under the Certificate of Designation.
View raw filing on EDGAR →
Hims & Hers Health, Inc.
Dilutive issuance
confidence 92%
filed 2026-05-19
Item 8.01
The Company disclosed a private offering of Convertible Senior Notes due 2032 to qualified institutional buyers pursuant to Rule 144A. Convertible notes are dilutive securities that may result in issuance of Class A common stock upon conversion, making this a dilutive issuance material to investors assessing capital structure and potential equity dilution.
View raw filing on EDGAR →
RAPID MICRO BIOSYSTEMS, INC.
Dilutive issuance
confidence 95%
filed 2026-05-19
Item 1.01
The Company entered into an underwriting agreement on May 18, 2026, to conduct an underwritten public offering of 3,581,000 shares of Class A common stock plus pre-funded warrants and multiple series of warrants, with net proceeds of approximately $8.9 million. Additionally, a concurrent registered direct offering to directors and officers for 71,607 shares was executed. These are registered equity issuances that will dilute existing shareholders and raise capital, fitting the dilutive_issuance category. The materiality is clear given the substantial number of shares being issued and the capital raised.
View raw filing on EDGAR →
UNIVERSAL SAFETY PRODUCTS, INC.
Dilutive issuance
confidence 95%
filed 2026-05-19
Item 3.02
The filing discloses unregistered issuances of equity securities totaling 310,575 shares upon conversion of a convertible note, relying on Section 4(a)(2) exemption. This represents a dilutive capital event where the company issued approximately 10.3% of its outstanding shares (310,575 of 3,028,362 shares) to satisfy debt obligations, which is material to investors assessing ownership dilution and the company's capital structure.
View raw filing on EDGAR →
Exyn Technologies, Inc.
Dilutive issuance
confidence 92%
filed 2026-05-19
Item 3.02
The filing discloses an unregistered issuance of warrants to purchase 71,875 shares of Common Stock to Lucid (the underwriter) as underwriting compensation in connection with the IPO closing. This is a classic dilutive issuance under Item 3.02, relying on Section 4(a)(2) exemption. The warrant grant to the underwriter is material to investors assessing post-IPO ownership dilution and capital structure.
View raw filing on EDGAR →
Kimbell Royalty Partners, LP
Dilutive issuance
confidence 92%
filed 2026-05-19
Item 3.02
Item 3.02 discloses private placements of OpCo Common Units and Class B Units under a Purchase Agreement, relying on Section 4(a)(2) exemption from Securities Act registration. The disclosure of unregistered equity issuances with future exchange rights is a classic dilutive issuance event that would materially affect investor assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
Alaska Silver Corp.
Dilutive issuance
confidence 75%
filed 2026-05-19
Item 5.02
The Board approved debt-to-equity conversion agreements with four creditors (including the CEO and VP Administration) whereby the Company will issue 1,509,710 common shares in aggregate to settle approximately C$1.24 million in deferred management fees. This is a dilutive issuance of equity securities to settle debt, subject to regulatory approvals and shareholder vote. While technically a debt settlement, the core disclosure centers on the issuance of a substantial number of shares to insiders, which is material to investors assessing ownership dilution and related-party transactions.
View raw filing on EDGAR →
InMed Pharmaceuticals Inc.
Dilutive issuance
confidence 85%
filed 2026-05-19
Item 1.01
The Company amended preferred investment options with Armistice Capital, dramatically reducing the exercise price from $16.60 to $0.80 per share on 278,761 common shares. This substantial downward repricing of equity warrants significantly increases the likelihood of exercise and dilution to existing shareholders, making it a material dilutive event. The amendment effectively converts out-of-the-money options into deeply in-the-money instruments, which is a classic signal of dilutive equity issuance activity.
View raw filing on EDGAR →
FEDERAL AGRICULTURAL MORTGAGE CORP
Dilutive issuance
confidence 85%
filed 2026-05-19
Item 8.01
Farmer Mac completed an issuance of 4,000,000 shares of preferred stock in an exempt public offering on May 19, 2026. While this is a preferred stock issuance rather than common equity, it represents a material capital raise that dilutes existing shareholders' ownership and is typically disclosed under Item 3.02 (Unregistered Sales) or Item 8.01 (Other Events). The issuance of 4 million shares of preferred stock with a stated dividend rate (6.875%) is material to investors assessing the company's capital structure and financing activities.
View raw filing on EDGAR →
CAPITAL SOUTHWEST CORP
Dilutive issuance
confidence 92%
filed 2026-05-19
Item 1.01
Capital Southwest Corporation amended its at-the-market (ATM) offering program on May 19, 2026, increasing the maximum aggregate offering amount from $1.0 billion to $2.0 billion through sixth amendments to equity distribution agreements with four sales agents (Jefferies, Raymond James, Citizens Capital Markets, and B. Riley). This is a material dilutive issuance under Item 1.01, as it substantially expands the company's capacity to issue common stock and would materially affect shareholder equity and voting power.
View raw filing on EDGAR →
RMX INDUSTRIES, INC.
Dilutive issuance
confidence 92%
filed 2026-05-18
Item 3.02
Item 3.02 discloses unregistered sales of equity securities under an IP Purchase Agreement and Subscription Agreement to accredited investors (Apollo and other investors) in reliance on Section 4(a)(2) and Regulation D Rule 506(b). This is a classic private placement of equity securities exempt from registration, which is material to investors as it signals capital raising and potential dilution to existing shareholders.
View raw filing on EDGAR →